GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Shares Outstanding (EOP)

Allergy Therapeutics (Allergy Therapeutics) Shares Outstanding (EOP)

: 4,766.44 Mil (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Allergy Therapeutics's shares outstanding for the quarter that ended in Dec. 2023 was 4,766.44 Mil.

Allergy Therapeutics's quarterly shares outstanding increased from Jun. 2023 (688.95 Mil) to Dec. 2023 (4,766.44 Mil). It means Allergy Therapeutics issued new shares from Jun. 2023 to Dec. 2023 .

Allergy Therapeutics's annual shares outstanding increased from Jun. 2022 (644.11 Mil) to Jun. 2023 (688.95 Mil). It means Allergy Therapeutics issued new shares from Jun. 2022 to Jun. 2023 .


Allergy Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Allergy Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shares Outstanding (EOP)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 636.17 637.29 651.62 644.11 688.95

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (EOP) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 643.60 644.11 679.11 688.95 4,766.44

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics Shares Outstanding (EOP) Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Shares Outstanding (EOP) falls into.



Allergy Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Allergy Therapeutics  (OTCPK:AGYTF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Allergy Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines